Seven Eight Capital’s Royalty Pharma RPRX Stock Holding History

Seven Eight Capital’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-12,830	Closed	-$348K	–	804
2023 Q3	$348K	Sell	12,830 -19,074	-60%	-$567K	0.04%	470
2023 Q2	$981K	Buy	+31,904	New	+$1.08M	0.16%	183
2023 Q1	–	Sell	-12,465	Closed	-$493K	–	586
2022 Q4	$493K	Sell	12,465 -1,534	-11%	-$64K	0.13%	228
2022 Q3	$562K	Buy	+13,999	New	+$598K	0.11%	254
2022 Q2	–	Sell	-8,135	Closed	-$317K	–	587
2022 Q1	$317K	Buy	+8,135	New	+$319K	0.04%	400

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Seven Eight Capital's RPRX Position: Q4 2023 in Review

Seven Eight Capital sold out of Royalty Pharma (RPRX) in Q4 2023, closing a stake of 12,830 shares — an estimated $348K sold.

Seven Eight Capital first reported a position in RPRX in Q1 2022 and held it in 5 quarters. The position peaked at $981K in Q2 2023. 363 funds tracked by Wall St. Rank hold RPRX as of Q4 2023.

Seven Eight Capital reported no remaining Royalty Pharma position as of Q4 2023 after selling out during the quarter.
Seven Eight Capital sold 12,830 Royalty Pharma shares in Q4 2023, an estimated $348K.
Seven Eight Capital first reported a position in Royalty Pharma in Q1 2022 and held it in 5 quarters.
Seven Eight Capital's Royalty Pharma position peaked at $981K in Q2 2023.
363 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2023.

Based on Seven Eight Capital's 13F filing for Q4 2023, filed 13 Feb 2024.